SCHEMBL6560643

SCHEMBL6560643

COc1ccc(S(=O)(=O)Nc2ccccc2N)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 4/20 0.70
NFE2L2 Q16236 2/20 0.68
SQSTM1 Q13501 1/20 0.68
GAA P10253 2/20 0.63
KMT2A Q03164 1/20 0.63
HDAC1 Q13547 4/20 0.60
HDAC3 O15379 3/20 0.60
NCOR2 Q9Y618 3/20 0.60
HDAC2 Q92769 2/20 0.60
TUBB4A P04350 1/20 0.59
TUBB P07437 1/20 0.59
TUBA3C P0DPH7 1/20 0.59
TUBA1B P68363 1/20 0.59
TUBA4A P68366 1/20 0.59
TUBB4B P68371 1/20 0.59
TUBB3 Q13509 1/20 0.59
TUBB2A Q13885 1/20 0.59
TUBB8 Q3ZCM7 1/20 0.59
TUBA3E Q6PEY2 1/20 0.59
TUBA1A Q71U36 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12768028 0.89 KEAP1 (0.81) KEAP1NFE2L2SQSTM1GAAKMT2A
SCHEMBL5595259 0.84 PGR (0.59) KEAP1KMT2AALDH1A1LMNAHPGD
SCHEMBL6561666 0.84 SQSTM1 (0.70) KEAP1NFE2L2SQSTM1GAAKMT2A
SCHEMBL10143424 0.83 KEAP1 (0.72) KEAP1NFE2L2SQSTM1GAAKMT2A
SCHEMBL27995939 0.83 KEAP1 (0.72) KEAP1NFE2L2SQSTM1GAAKMT2A
SCHEMBL23555177 0.83 KEAP1 (1.00) KEAP1NFE2L2SQSTM1GAAKMT2A
SCHEMBL789616 0.83 KEAP1 (0.72) KEAP1NFE2L2SQSTM1GAAKMT2A
SCHEMBL23443367 0.82 KEAP1 (1.00) KEAP1NFE2L2SQSTM1GAAALDH1A1
SCHEMBL398000 0.82 LMNA (0.70) KEAP1NFE2L2GAAKMT2AHDAC1
SCHEMBL6563645 0.81 KEAP1 (0.56) KEAP1NFE2L2SQSTM1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216954-B2 Serine racemase inhibitor NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) 2015-12-22 US disclosed
US-9216954-B2 Serine racemase inhibitor NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) 2015-12-22 US disclosed
US-20140371291-A1 SERINE RACEMASE INHIBITOR NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) 2014-12-18 US disclosed
US-20140371291-A1 SERINE RACEMASE INHIBITOR NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) 2014-12-18 US disclosed
EP-2808014-A1 SERINE RACEMASE INHIBITOR National University Corporation University Of Toyama (JP) 2014-12-03 EP disclosed
EP-2808014-A1 SERINE RACEMASE INHIBITOR National University Corporation University Of Toyama (JP) 2014-12-03 EP disclosed
WO-2013111798-A1 SERINE RACEMASE INHIBITOR 国立大学法人 富山大学 (JP) 2013-08-01 WO disclosed
EP-0990645-B1 NOVEL SULFONAMIDE DERIVATIVES NIPPON KAYAKU KK (JP) 2004-07-28 EP disclosed
US-6458960-B1 ANTICANCER AGENTS, RHEUMATIC DISEASES AND ANTIINFLAMMATORY AGENTS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2002-10-01 US disclosed
US-6180796-B1 TUBULIN POLYMERIZATION INHIBITORS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2001-01-30 US disclosed
EP-0990645-A1 NOVEL SULFONAMIDE DERIVATIVES Nippon Kayaku Kabushiki Kaisha (JP) 2000-04-05 EP disclosed
EP-0472053-B1 Sulfonamide derivatives EISAI CO LTD (JP) 1998-06-17 EP disclosed
US-5610304-A Pyrimidinyl or pyridinyl sulfonamide substituted compounds EISAI CO., LTD. (JP) 1997-03-11 US disclosed
US-5610320-A ANTITUMOR AGENTS EISAI CO., LTD. (JP) 1997-03-11 US disclosed
US-5434172-A Antitumor EISAI CO., LTD. (JP) 1995-07-18 US disclosed
US-5332751-A Antitumor EISAI CO., LTD. (JP) 1994-07-26 US disclosed
US-5292758-A Sulfonamide derivatives EISAI CO., LTD. (JP) 1994-03-08 US disclosed
US-5250549-A Antitumor agents EISAI CO., LTD. (JP) 1993-10-05 US disclosed
EP-0472053-A2 Sulfonamide derivatives Eisai Co., Ltd. (JP) 1992-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371291-A1 SERINE RACEMASE INHIBITOR SRR, PRSS1, ME1 KEAP1 565/4885NFE2L2 3793/4885SQSTM1 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.